scispace - formally typeset
B

Beth Jackson

Researcher at Merck & Co.

Publications -  8
Citations -  1089

Beth Jackson is an academic researcher from Merck & Co.. The author has contributed to research in topics: Medicine & Elbasvir. The author has an hindex of 5, co-authored 6 publications receiving 644 citations.

Papers
More filters
Journal ArticleDOI

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair Munro, +314 more
- 02 Dec 2021 - 
TL;DR: The COV-BOOST trial as mentioned in this paper investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer-BioNtech, hearafter referred to As BNT).
Journal ArticleDOI

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, +7885 more
- 03 Mar 2022 - 
TL;DR: In patients hospitalised with COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials.